Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Double-blind, Randomized, Placebo-controlled, Multi-country and Multi-center Study to Assess the Efficacy and Safety of Two Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine in Healthy Infants.

NCT00329745 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00329745
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00329745 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Double-blind, Randomized, Placebo-controlled, Multi-country and Multi-center Study to Assess the Efficacy and Safety of Two Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine in Healthy Infants.
Lead sponsor
GlaxoSmithKline
Phase
Phase 3
Overall status
Completed
Start date
January 31, 2007
Completion date
July 31, 2008
Enrollment
8,687 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

infections, rotavirus